Telix Pharmaceuticals Files 2024 Annual Report & Results
Ticker: TLPPF · Form: 6-K · Filed: Feb 21, 2025 · CIK: 2007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLPPF) |
| Form Type | 6-K |
| Filed Date | Feb 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, corporate-governance, financial-results
TL;DR
Telix dropped its 2024 annual report and full-year results on Feb 20th - check it for the latest financials.
AI Summary
On February 20, 2025, Telix Pharmaceuticals Limited filed its Appendix 4E and 2024 Annual Report, along with its Appendix 4G and 2024 Corporate Governance Statement and 2024 Full Year Results with the Australian Securities Exchange. These filings provide a comprehensive overview of the company's performance and governance for the fiscal year ending December 31, 2024.
Why It Matters
This filing provides investors with the company's audited financial performance and governance practices for the past fiscal year, crucial for assessing its current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine annual report filing and does not contain new material events or significant financial changes.
Key Players & Entities
- Telix Pharmaceuticals Limited (company) — Filer of the report
- February 20, 2025 (date) — Date of filing announcements
- Australian Securities Exchange (company) — Exchange where announcements were filed
- December 31, 2024 (date) — Fiscal year end
FAQ
What specific financial results were announced on February 20, 2025?
The filing mentions the '2024 Full Year Results' were announced, but the specific financial figures are detailed within the Appendix 4E and 2024 Annual Report, which are separate documents filed concurrently.
What is the significance of Appendix 4E and Appendix 4G?
Appendix 4E is an Australian Securities Exchange (ASX) requirement for preliminary final reporting, summarizing full-year financial results. Appendix 4G details a company's compliance with the ASX Corporate Governance Council's Principles and Recommendations.
Does this 6-K filing contain the actual financial statements?
No, this 6-K filing serves as a cover document to announce that Telix Pharmaceuticals Limited has filed its Appendix 4E, 2024 Annual Report, Appendix 4G, and 2024 Corporate Governance Statement with the ASX. The detailed financial statements are within those referenced documents.
What is the company's fiscal year end?
Telix Pharmaceuticals Limited's fiscal year ends on December 31.
Where is Telix Pharmaceuticals Limited headquartered?
The company's principal executive offices are located at 55 Flemington Road, North Melbourne, Victoria 3051, Australia.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 21, 2025 regarding Telix Pharmaceuticals Ltd (TLPPF).